Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., a leading player in the diagnostics industry, is headquartered in the United States and operates across various regions globally. Founded in 1985, the company has established itself as a pioneer in the development of innovative point-of-care testing solutions, particularly in infectious disease diagnostics. Chembio's core products include rapid tests for diseases such as HIV, syphilis, and malaria, distinguished by their accuracy and speed. The company’s unique dual-path technology enhances test performance, setting it apart in a competitive market. With a commitment to improving patient outcomes, Chembio has achieved significant milestones, including partnerships with global health organisations. Recognised for its contributions to public health, Chembio Diagnostics continues to strengthen its market position through ongoing research and development, ensuring it remains at the forefront of diagnostic innovation.
DitchCarbon Score
How does Chembio Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chembio Diagnostics, Inc.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chembio Diagnostics, Inc.'s reported carbon emissions
Chembio Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Biosynex SA, which may influence its climate commitments and reporting practices. While Chembio has not set explicit reduction targets or initiatives, it is important to note that the broader industry context often drives companies to adopt sustainable practices. As a subsidiary, Chembio may align its climate strategies with those of its parent company, Biosynex SA, which could include participation in initiatives such as the Carbon Disclosure Project (CDP) at a cascade level of 1. In the absence of specific emissions data or reduction targets, Chembio Diagnostics, Inc. remains committed to exploring avenues for sustainability and may benefit from the climate strategies of its parent organisation.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chembio Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
